BetterLife’s Non-hallucinogenic LSD (BETR-001) For Treating Mood Disorders Highlighted in Drug Discovery & Development Article Post published:March 29, 2023 Post category:Press Release
Promise of BetterLife’s Non-hallucinogenic LSD (BETR-001) For Treating Mood Disorders Highlighted in Medical Xpress Article Post published:March 22, 2023 Post category:Press Release
CORRECTION — BetterLife Closes $1,857,143 of Private Placement Post published:March 14, 2023 Post category:Press Release
BetterLife Closes $1,857,143 of Private Placement Post published:March 14, 2023 Post category:Press Release
BetterLife Files Amended and Restated Offering Document for Offering of Units Post published:March 11, 2023 Post category:Press Release
Betterlife Publishes Promising Results from a Study Titled “A Non-Hallucinogenic LSD Analog With Therapeutic Potential For Mood Disorders” Post published:March 9, 2023 Post category:Press Release
BetterLife Announces Pricing of Proposed Offering of Units Post published:March 8, 2023 Post category:Press Release
BetterLife Announces Engagement of Bloom Burton Securities Inc. and Provides Summary of 2022 Accomplishments Post published:January 27, 2023 Post category:Press Release
BetterLife Announces Closing of Private Placement Post published:December 7, 2022 Post category:Press Release